The sphingosine phosphate receptors 1 and 3 (S1PR1 and S1PR3) are upregulated by astrocytes in MS lesions [95–97], and their modulation by the FDA-approved MS drug and sphingosine analog fingolimod has beneficial anti-inflammatory and neurotrophic effects not only in MS but also in AD mouse models [98–101]. Here, S1PR1 is linked to myeloid sarcoma.